Pfizer’s Phase 3 trial of gene therapy for Duchenne muscular dystrophy without significant results October 16, 2024 Pharma & Biotech Pfizer's Phase 3 trial of gene therapy for Duchenne muscular dystrophy shows no significant results. Future research will be supported by detailed data. Continue Reading
